Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community

AI-generated source summary

The video provides a fundamental analysis of Pfizer (PFE). The analysis emphasizes the impact of policy changes in the pharmaceutical sector and the ongoing uncertainty due to changing tariff policies under the current administration. It highlights the gap between the calculated intrinsic value per share of Pfizer at $75.25, with the market price at $27.37. The analyst explicitly reiterates a 'buy' rating for Pfizer, appealing to long-term investors based on the expectation that the company will outlast current policy implementations. The analysis is based around the difference of the current market price and the calculated value of the company taking into account market volatility due to constant policy and tariff changes, and estimates a buy for Pfizer at 75.25

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   06 Oct 2025, 22:35 UTC

   The analyst published the original source item.

2. First prediction resolved

   08 Oct 2025, 14:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   08 Oct 2025, 14:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:13 UTC

   Tahlil Plus began monitoring the extracted predictions.